440 related articles for article (PubMed ID: 35628495)
1. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.
Shin HG; Yang HR; Yoon A; Lee S
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628495
[TBL] [Abstract][Full Text] [Related]
2. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
[TBL] [Abstract][Full Text] [Related]
3. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
4. Are BiTEs the "missing link" in cancer therapy?
Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
[TBL] [Abstract][Full Text] [Related]
5. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
6. Recent advances of bispecific antibodies in solid tumors.
Yu S; Li A; Liu Q; Yuan X; Xu H; Jiao D; Pestell RG; Han X; Wu K
J Hematol Oncol; 2017 Sep; 10(1):155. PubMed ID: 28931402
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
Zhang M; Lam KP; Xu S
Front Immunol; 2023; 14():1207276. PubMed ID: 37638058
[TBL] [Abstract][Full Text] [Related]
8. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
9. Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody.
Moon D; Tae N; Park Y; Lee SW; Kim DH
Immune Netw; 2022 Feb; 22(1):e4. PubMed ID: 35291652
[TBL] [Abstract][Full Text] [Related]
10. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
Cech P; Skórka K; Dziki L; Giannopoulos K
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672662
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies for immune cell retargeting against cancer.
Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
[TBL] [Abstract][Full Text] [Related]
12. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
Blanco B; Domínguez-Alonso C; Alvarez-Vallina L
Clin Cancer Res; 2021 Oct; 27(20):5457-5464. PubMed ID: 34108185
[TBL] [Abstract][Full Text] [Related]
13. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
14. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy.
Fucà G; Spagnoletti A; Ambrosini M; de Braud F; Di Nicola M
ESMO Open; 2021 Feb; 6(1):100046. PubMed ID: 33508733
[TBL] [Abstract][Full Text] [Related]
15. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
Zorko NA; Ryan CJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
Demaria O; Gauthier L; Debroas G; Vivier E
Eur J Immunol; 2021 Aug; 51(8):1934-1942. PubMed ID: 34145579
[TBL] [Abstract][Full Text] [Related]
17. Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications.
Zhu Y; Shen R; Hao R; Wang S; Ho M
Antib Ther; 2020 Apr; 3(2):146-154. PubMed ID: 32671329
[TBL] [Abstract][Full Text] [Related]
18. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
[TBL] [Abstract][Full Text] [Related]
19. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
He Y; Helfrich W; Bremer E
Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
[TBL] [Abstract][Full Text] [Related]
20. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
